Inhibition of Nuclear Factor of Activated T-Cells (NFAT) Suppresses Accelerated Atherosclerosis in Diabetic Mice

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Zetterqvist, Anna V ^a   Berglund, Lisa M ^a   Blanco, Fabiana ^a   Garcia Vaz, Eliana ^a   Wigren, Maria ^a   Dunér, Pontus ^a   Andersson, Anna Maria Dutius ^a   To, Fong ^a   Spegel, Peter ^a   Nilsson, Jan ^a   Bengtsson, Eva ^a   Gomez, Maria F ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

A 285222; ANTIDIABETIC AGENT; APOLIPOPROTEIN E; CHLORDANE; CHOLESTEROL; CYCLOOXYGENASE 2; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; THROMBOPLASTIN; TRANSCRIPTION FACTOR NFAT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CELL ACTIVATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HISTOPATHOLOGY; HYPERGLYCEMIA; IN VIVO STUDY; MASS FRAGMENTOGRAPHY; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLEEN CELL; STREPTOZOCIN DIABETES; TRANSCRIPTION INITIATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BLOOD; BODY WEIGHT; C57BL MOUSE; COMPLICATION; DEFICIENCY; DISEASE COURSE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; INFLAMMATION; METABOLISM; PATHOLOGY; THORACIC AORTA;

MUS;

ANIMALS; AORTA, THORACIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DISEASE PROGRESSION; INFLAMMATION; INTERLEUKIN-6; MICE, INBRED C57BL; MONOCYTES; NFATC TRANSCRIPTION FACTORS; PLAQUE, ATHEROSCLEROTIC; PYRAZOLES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84878655746     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065020     Document Type: Article

References (43)

1. Rahman S, Rahman T, Ismail AA, Rashid AR, (2007) Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 9: 767-780.
2. Coutinho M, Gerstein HC, Wang Y, Yusuf S, (1999) The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22: 233-240.
3. Rasmussen-Torvik LJ, Li M, Kao WH, Couper D, Boerwinkle E, et al. (2011) Association of a Fasting Glucose Genetic Risk Score With Subclinical Atherosclerosis. Diabetes 60: 331-335.
4. Brown A, Reynolds LR, Bruemmer D, (2010) Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 7: 369-375.
5. Nilsson J, Nilsson LM, Chen Y-W, Molkentin JD, Erlinge D, et al. (2006) High Glucose Activates Nuclear Factor of Activated T Cells in Native Vascular Smooth Muscle. Arterioscler Thromb Vasc Biol 26: 794-800.
6. Nilsson-Berglund LM, Zetterqvist AV, Nilsson-Ohman J, Sigvardsson M, Gonzalez Bosc LV, et al. (2009) Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia. Arterioscler Thromb Vasc Biol 30: 218-224.
7. Nilsson LM, Sun ZW, Nilsson J, Nordstrom I, Chen YW, et al. (2007) Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol 292: C1167-1178.
8. Orr AW, Lee MY, Lemmon JA, Yurdagul A, Gomez MF, et al. (2008) Molecular Mechanisms of Collagen Isotype-Specific Modulation of Smooth Muscle Cell Phenotype. Arterioscler Thromb Vasc Biol 29: 225-231.
9. Nilsson LM, Nilsson-Ohman J, Zetterqvist AV, Gomez MF, (2008) Nuclear factor of activated T-cells transcription factors in the vasculature: the good guys or the bad guys? Curr Opin Lipidol 19: 483-490.
10. Liu Z, Dronadula N, Rao GN, (2004) A Novel Role for Nuclear Factor of Activated T Cells in Receptor Tyrosine Kinase and G Protein-coupled Receptor Agonist-induced Vascular Smooth Muscle Cell Motility. J Biol Chem 279: 41218-41226.
11. Karpurapu M, Wang D, Van Quyen D, Kim T-K, Kundumani-Sridharan V, et al. (2010) Cyclin D1 Is a Bona Fide Target Gene of NFATc1 and Is Sufficient in the Mediation of Injury-induced Vascular Wall Remodeling. Journal of Biological Chemistry 285: 3510-3523.
12. Lipskaia L, del Monte F, Capiod T, Yacoubi S, Hadri L, et al. (2005) Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res 97: 488-495.
13. Lee MY, Garvey SM, Baras AS, Lemmon JA, Gomez MF, et al. (2009) Integrative genomics identifies DSCR1 (RCAN1) as a novel NFAT-dependent mediator of phenotypic modulation in vascular smooth muscle cells. Hum Mol Genet 19: 468-479.
14. Amberg GC, Rossow CF, Navedo MF, Santana LF, (2004) NFATc3 regulates Kv2.1 expression in arterial smooth muscle. J Biol Chem 279: 47326-47334.
15. Nieves-Cintron M, Amberg GC, Nichols CB, Molkentin JD, Santana LF, (2007) Activation of NFATc3 down-regulates the beta1 subunit of large conductance, calcium-activated K+ channels in arterial smooth muscle and contributes to hypertension. J Biol Chem 282: 3231-3240.
16. Berglund LM, Kotova O, Osmark P, Grufman H, Xing C, et al. (2011) NFAT regulates the expression of AIF-1 and IRT-1: yin and yang splice variants of neointima formation and atherosclerosis. Cardiovasc Res 93: 414-423.
17. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, et al. (2004) Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94: 110-118.
18. Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu KY, et al. (2003) Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 23: 879-884.
19. Prévost G, Bulckaen H, Gaxatte C, Boulanger E, Béraud G, et al. (2011) Structural modifications in the arterial wall during physiological aging and as a result of diabetes mellitus in a mouse model: Are the changes comparable? Diabetes & Metabolism 37: 106-111.
20. Gustavsson C, Agardh CD, Zetterqvist AV, Nilsson J, Agardh E, et al. (2010) Vascular cellular adhesion molecule-1 (VCAM-1) expression in mice retinal vessels is affected by both hyperglycemia and hyperlipidemia. PLoS One 5: e12699.
21. Awla D, Zetterqvist AV, Abdulla A, Camello C, Berglund LM, et al. (2012) NFATc3 Regulates Trypsinogen Activation, Neutrophil Recruitment, and Tissue Damage in Acute Pancreatitis in Mice. Gastroenterology: Jul 27. [Epub ahead of print].
22. Wigren M, Bengtsson D, Duner P, Olofsson K, Bjorkbacka H, et al. (2009) Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ Res 104: e62-70.
23. Wigren M, Bjãrkbacka H, Andersson L, Ljungcrantz I, Fredrikson GN, et al. (2012) Low Levels of Circulating CD4+FoxP3+ T Cells Are Associated With an Increased Risk for Development of Myocardial Infarction But Not for Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology 32: 2000-2004.
24. Engelbertsen D, Andersson L, Ljungcrantz I, Wigren M, Hedblad B, et al. (2013) T-Helper 2 Immunity Is Associated With Reduced Risk of Myocardial Infarction and Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology 33: 637-644.
25. Kolbus D, Ramos OH, Berg KE, Persson J, Wigren M, et al. (2010) CD8+ T cell activation predominate early immune responses to hypercholesterolemia in Apoe(-)(/)(-) mice. BMC Immunol 11: 58.
26. Reddick RL, Zhang SH, Maeda N, (1994) Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb 14: 141-147.
27. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, et al. (1997) Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17: 439-444.
28. Shi W, Brown MD, Wang X, Wong J, Kallmes DF, et al. (2003) Genetic Backgrounds but Not Sizes of Atherosclerotic Lesions Determine Medial Destruction in the Aortic Root of Apolipoprotein Eâ€"Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 23: 1901-1906.
29. Lohmann C, Schafer N, von Lukowicz T, Sokrates Stein MA, Boren J, et al. (2009) Atherosclerotic mice exhibit systemic inflammation in periadventitial and visceral adipose tissue, liver, and pancreatic islets. Atherosclerosis 207: 360-367.
30. Birsan T, Dambrin C, Marsh KC, Jacobsen W, Djuric SW, et al. (2004) Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin-independent inhibitor of NFAT. Transpl Int 3: 145-150.
31. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R, (1994) ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14: 133-140.
32. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, et al. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4: 1025-1031.
33. Lipskaia L, Pourci M-L, Delomenie C, Combettes L, Goudouneche D, et al. (2003) Phosphatidylinositol 3-Kinase and Calcium-Activated Transcription Pathways Are Required for VLDL-Induced Smooth Muscle Cell Proliferation. Circ Res 92: 1115-1122.
34. Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, et al. (2007) Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 193: 321-327.
35. Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, et al. (2002) Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood 99: 199-206.
36. Maziere C, Morliere P, Massy Z, Kamel S, Louandre C, et al. (2005) Oxidized low-density lipoprotein elicits an intracellular calcium rise and increases the binding activity of the transcription factor NFAT. Free Radic Biol Med 38: 472-480.
37. Schuett H, Luchtefeld M, Grothusen C, Grote K, (2009) Schieffer B (2009) How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 102: 215-222.
38. Takeda N, Manabe I, Shindo T, Iwata H, Iimuro S, et al. (2006) Synthetic retinoid Am80 reduces scavenger receptor expression and atherosclerosis in mice by inhibiting IL-6. Arterioscler Thromb Vasc Biol 26: 1177-1183.
39. Abbott KL, Loss JR, Robida AM, Murphy TJ, (2000) Evidence that Galpha(q)-coupled receptor-induced interleukin-6 mRNA in vascular smooth muscle cells involves the nuclear factor of activated T cells. Mol Pharmacol 58: 946-953.
40. Trevillyan JM, Chiou XG, Chen YW, Ballaron SJ, Sheets MP, et al. (2001) Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. J Biol Chem 276: 48118-48126.
41. Breitenstein A, Camici GG, Tanner FC, (2010) Tissue factor: beyond coagulation in the cardiovascular system. Clin Sci (Lond) 118: 159-172.
42. Kockx M, Jessup W, Kritharides L, (2010) Cyclosporin A and atherosclerosis-cellular pathways in atherogenesis. Pharmacol Ther 128: 106-118.
43. Donners MM, Bot I, De Windt LJ, van Berkel TJ, Daemen MJ, et al. (2005) Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. Am J Transplant 5: 1204-1215.